Objective To investigate the application of Apalutamide in the treatment of metastatic hormone-sensitive prostate cancer.Methods A total of 80 patients diagnosed with metastatic hormone-sensitive prostate cancer(mHSPC)in the First People's Hospital of Jiujiang from June 2019 to June 2022 were selected and divided into observation group and control group according to lottery method,with 40 cases in each group.The control group was treated with Bicalutamide combined with androgen deprivation therapy(ADT),and the observation group was treated with Apalutamide combined with ADT.Clinical efficacy,prostate-specific antigen(PSA)response time,time to PSA progression,time to castration-resistant prostate cancer(CRPC),and drug-related adverse reactions were evaluated in both groups.Results The total clinical effec-tive rate of observation group was higher than that of control group,the difference was statistically significant(P＜0.05).The PSA response time of observation group was shorter than that of control group,and the difference was statistically significant(P＜0.05).The progression time of PSA in observation group was longer than that in control group,and the difference was statistically significant(P＜0.05).The time to CRPC in observation group was significantly longer than that in control group,and the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse drug reactions between the two groups(P＞0.05).Conclusion The new endocrine drug Apalutamide combined with ADT is ef-fective in the treatment of mHSPC patients,which can realize PSA response more quickly,delay PSA progression to CRPC,and have relatively high safety and low drug-related adverse reactions.
维普
万方数据